Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura E Trask

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Chemistry|March 2, 2012
Low hemoglobin A(1c)--good diabetic control?Laura E Trask, Diane Abbott, Hong-Kee Lee
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 22, 2013
Safety and efficacy of the nonsystemic chewable complex carbohydrate dietary supplement PAZ320 on postprandial glycemia when added to oral agents or insulin in patients with type 2 diabetes mellitusLaura E Trask, Natasha Kasid, Karen Homa, et al.
Journal of Diabetes Science and Technology|August 31, 2014
Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulinLaura E Trask, Sushela S Chaidarun, David Platt, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Chemistry|March 2, 2012
Low hemoglobin A(1c)--good diabetic control?Laura E Trask, Diane Abbott, Hong-Kee Lee
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|February 22, 2013
Safety and efficacy of the nonsystemic chewable complex carbohydrate dietary supplement PAZ320 on postprandial glycemia when added to oral agents or insulin in patients with type 2 diabetes mellitusLaura E Trask, Natasha Kasid, Karen Homa, et al.
Journal of Diabetes Science and Technology|August 31, 2014
Treatment with novel galactomannan derivative reduces 2-hour postprandial glucose excursions in individuals with type 2 diabetes treated with oral medications and/or insulinLaura E Trask, Sushela S Chaidarun, David Platt, et al.
Pageof 1